MIAMI BEACH, FLORIDA -- October 3, 2011 -- A key global healthcare challenge is the dramatic increase in cancer incidence. According to World Health Organization data, cancer rates could increase by 50 percent, leading to 15 million new cases in 2020. Oncology specialists connect and interact with each other throughout the cancer care continuum, all with the goal of providing the best possible care for their patients.
First FDA-approved imaging agent of its kind in the United States
PRINCETON, NJ, JUNE 28, 2011 -- GE Healthcare today announced the availability of DaTscan™ (Ioflupane I 123 Injection), in more than 80 hospitals across the US. DaTscan is the first FDA-approved radiopharmaceutical adjunct imaging agent to help physicians evaluate patients with suspected parkinsonian syndromes (PS), such as Parkinson's disease (PD). It gives physicians diagnostic capability that may lead to timely, appropriate treatments for suspected PS patients.
GE Healthcare takes steps to engage midwives in the development of tools and resources that can further the midwifery practice and improve maternal and infant care around the world
Durban, SOUTH AFRICA; June 20, 2011: Midwives have a substantial impact on the wellbeing of women and newborns. GE Healthcare is celebrating the role midwives play in the birthing experience at the International Confederation of Midwives (ICM) 2011 Congress on June 19 -- 23 in Durban, South Africa.
GE Healthcare, a unit of General Electric Company (NYSE:GE) announced today that it has completed the tender offer by GE's wholly owned subsidiary, Crane Merger Sub, Inc., for all outstanding shares of common and preferred stock of Clarient Inc., a leading player in the fast-growing molecular diagnostics sector.
Technologies foster better, more efficient care with improvements in image quality, dose management and clinician workflow
CHICAGO--28 November 2010-- Increasing access. Improving quality and efficiency. Lowering costs. When GE launched its healthymagination initiative last year, these were the long-term goals and at RSNA 2010, GE Healthcare will highlight a variety of technologies developed to support this strategy and help improve patient care worldwide.
PRINCETON, NJ -- July 12, 2010 -- GE Healthcare Medical Diagnostics today announced the market reintroduction of Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a diagnostic ultrasound contrast agent for use in select echocardiograms. Optison is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricle and to improve the delineation of the left ventricular endocardial borders. The safety and efficacy of Optison with exercise stress or pharmacologic stress testing have not been established.
